Mer­ck­'s Keytru­da scores first win in ad­ju­vant kid­ney can­cer, giv­ing it a leg up on check­point in­hibitor ri­vals

Mer­ck is mak­ing room for yet an­oth­er use on its Keytru­da la­bel — this time, as the first ad­ju­vant im­munother­a­py for cer­tain re­nal cell car­ci­no­ma pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER